Chronic Cannabis Users: A New Special Population to Consider for Drug Development.
Cannabis
cannabidiol
clinical pharmacology
delta-9-tetrahydrocannabinol
marijuana
special population
Journal
Current reviews in clinical and experimental pharmacology
ISSN: 2772-4336
Titre abrégé: Curr Rev Clin Exp Pharmacol
Pays: Netherlands
ID NLM: 9918227368306676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
11
2020
revised:
20
02
2021
accepted:
24
02
2021
pubmed:
31
8
2021
medline:
5
4
2022
entrez:
30
8
2021
Statut:
ppublish
Résumé
The use and acceptance of cannabis, either medically or recreationally, has substantially outpaced the collection of data necessary to evaluate it's use in any population. However, the mere widespread availability does not imply the absence of risk or confirmation of efficacy and should not be treated as such. There is enough data to suggest that not only does the potential for pharmacokinetic and metabolic interactions exist, but also that baseline characteristics for a given population could be different in chronic cannabis users. Either or both of these may impact the safety and efficacy profile for any new drug in development. As such, we encourage drug developers to consider that the cannabis user may very well be a special population that warrants its own clinical pharmacology evaluation.
Identifiants
pubmed: 34455949
pii: CRCEP-EPUB-115648
doi: 10.2174/2772432816666210515145638
doi:
Substances chimiques
Hallucinogens
0
Cannabidiol
19GBJ60SN5
Dronabinol
7J8897W37S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4-7Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.